The Na + -dependent amino acid transporter named ATB 0 was previously found to be located in 19q13.3 by fluorescence in situ hybridisation. Genetic heterogeneity in the 19q13.2-13.4 region, syntenic to the Cystic Fibrosis Modulator Locus 1 (CFM1) in mouse, seemed to be associated to the intestinal phenotypic variation of cystic fibrosis (CF). We performed fine chromosomal mapping of ATB 0 on radiation hybrid (RH) panels G3 and TNG. Based on the most accurate location results from TNG-RH panel, mapping analysis evidenced that ATB 0 is localised between STS SHGC-13875 (D19S995) and STS , that corresponds with the immediately telomeric/distal segment of the strongest linkage region within the human CFM1 (hCFM1) syntenic region. Regarding to the genomic structure and exon organisation, our results show that the ATB 0 gene is organised into eight exons. The knowledge of the genomic structure allowed us to perform an exhaustive mutational analysis of the gene. Evaluation of the possible implication of ATB 0 in the intestinal phenotype of CF was performed on the basis of the functional characteristics of the encoded protein, its apparent relevance to meconium ileus (MI) and position in relation to the hCFM1 syntenic region. We have analysed this gene in samples from CF patients with and without MI. Several sequence variations in the ATB 0 gene were identified, although none of them seemed to be related to the intestinal phenotype of CF. Even though no particular allele or haplotype in ATB 0 appears to be associated to CF-MI disease, new SNPs identified should be useful in segregation and linkage disequilibrium analyses in families affected by other disorders caused by the impairment of neutral amino acid transport. European Journal of Human Genetics (2001) 9, 860 ± 866.
The Na + -dependent amino acid transporter named ATB 0 was previously found to be located in 19q13.3 by fluorescence in situ hybridisation. Genetic heterogeneity in the 19q13.2-13.4 region, syntenic to the Cystic Fibrosis Modulator Locus 1 (CFM1) in mouse, seemed to be associated to the intestinal phenotypic variation of cystic fibrosis (CF). We performed fine chromosomal mapping of ATB 0 on radiation hybrid (RH) panels G3 and TNG. Based on the most accurate location results from TNG-RH panel, mapping analysis evidenced that ATB 0 is localised between STS SHGC-13875 (D19S995) and STS SHGC-6138 in 19q13. 3 , that corresponds with the immediately telomeric/distal segment of the strongest linkage region within the human CFM1 (hCFM1) syntenic region. Regarding to the genomic structure and exon organisation, our results show that the ATB 0 gene is organised into eight exons. The knowledge of the genomic structure allowed us to perform an exhaustive mutational analysis of the gene. Evaluation of the possible implication of ATB 0 in the intestinal phenotype of CF was performed on the basis of the functional characteristics of the encoded protein, its apparent relevance to meconium ileus (MI) and position in relation to the hCFM1 syntenic region. We have analysed this gene in samples from CF patients with and without MI. Several sequence variations in the ATB
Introduction
The transport of amino acids across the plasma membrane, essential for cellular metabolism, requires specialised transport proteins. 1 There are two amino acids transporter gene families based on ion dependence: Na + -independent and Na + -dependent. Na + -dependent transporters actively transport amino acids driven by the electrochemical gradient of Na + and concentrate them inside the cell. 2 The brush border membrane of the absorptive cells of the small intestine and kidney expresses a Na + -dependent, broad specificity, neutral amino acid transport system. This new member of this superfamily of transporters was cloned and named ATB 0 (neutral amino acid transporter B 0 ) 3 which indicates broad substrate specificity and preference for zwitterionic amino acids. It has also been named SLC1A5. 3, 4 Human ATB 0 (hATB 0 ) mRNA is detectable in placenta, lung, skeletal muscle, kidney and pancreas. 3 It was also reported to be expressed in rabbit jejunum and the human 
Materials and methods
Human ATB 0 radiation hybrid mapping
The chromosomal localisation of the gene was determined by PCR screening of the Stanford G3 and TNG 15 radiation hybrid panels. The ATB 0 gene was detected by using primers HNAT-8 and HNAT-9, 4 to produce a predicted 163 ± 173 bp product (depending on the length of the (GT) n sequence contained in the fragment amplified). Two-point linkage analysis was performed using the RHMAP-2.0 on the RH Server at the Stanford Human Genome Centre (http://wwwshgc.standford.edu/RH/index.html).
Genomic structure
To determine the genomic structure, the Blast N program was used to align genomic sequences (finished as well as unfinished) with the ATB 0 cDNA sequence (GeneBank accession no. U53347 and NM 005628).
Analysis of ATB 0 nucleotide changes DNA was isolated from peripheral blood lymphocytes as previously described. 16 After the deduction and identification of the different exons (Table 1) , ATB 0 DNA was amplified in eight segments (Table 2 ) comprising the 5'-and 3'-untranslated regions (UTR), coding exons and the immediately flanking intronic sequences of the gene. The 5'-fragment that incorporates 606 bp 5'-UTR and translation initiation site was amplified using the GC-rich PCR system (Roche Molecular Biochemicals, Indianapolis, IN, USA) due to its high content of Gs and Cs. Primers are described in Table 2 . Variations from wild type sequence were detected by SSCP/heteroduplex analysis. Direct automated sequencing for all abnormal bands was performed. A simple sequence repeat (GT) n in the 3'-UTR of ATB 0 was also determined by PCR for each sample. PCR parameters and primers were as previously described. 4 The amplified products were run on an AbiPrism 1 310 Genetic Analyser and the size was determined using Genotyper 1 software (v.
2.5) (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
The distribution of (GT) n alleles in the general population, CF-nonMI and CF-MI was examined by the Shapiro-Wilk test of normality and the Kruskal-Wallis non-parametric test. A binary logistic regression model was used to analyse the effect of (GT) n length on the phenotype. Contingency two-by-two tables with significance calculation using Yates' correction of w 2 test and the Fisher test to the European Journal of Human Genetics ATB 0 SLC1A5 gene and disease S Larriba et al 861 5% limit were employed to test for independence between physiological and genetic variables.
Subjects of study CF patients were clinically diagnosed and selected for the presence or absence of meconium ileus (MI). Twenty-five unrelated CF patients presented MI and pancreatic insufficiency. No signs of MI and pancreatic sufficiency were found in 23 CF patients. All of CF patients but one (with a clear CF phenotype) presented two CF mutations in their genotype after complete screening of the CFTR gene (Table 3 ). Four MI patients had a sibpair with an identical CF genotype but presented discordance of intestinal phenotype (Table 3) . Twenty-three non-CF subjects were also selected for the analysis of the distribution of the (GT) n allele and of the P17A and V512L mutations in Spanish general population.
Results

Chromosomal gene localisation
We have mapped the ATB 0 gene using primers that amplify a polymorphic (GT) n repeat in 3'-UTR 4 using the G3 and TNG radiation hybrid (RH) panels. These primers produce a single product when used to amplify human genomic DNA, but do not amplify sequences in hamster genomic DNA (data not shown Based on our RH mapping results and given the highest accuracy in the distance estimates obtained from the TNG RH panel, we conclude that the ATB 0 gene is located in the SHGC-13875 (D19S995) ± SHGC-6138 interval ( Figure 1 ).
Genomic structure of ATB 0
Two BAC clones from chromosome 19 were found to contain the coding region of ATB 0 gene by using BlastNhtgs database (unfinished sequences): GeneBank accession nos. AC025983 (44 pieces) and AC008622 (27 pieces). The genomic structure of ATB 0 was determined by comparing the sequence of the BAC with ATB 0 cDNA sequence (accession no. U53347). The BAC no. AC025983 was selected due to the highest identity with the cDNA sequence. This allowed us to determine the exon/intron boundaries of the gene. Eight exons were identified ( Table  1 ) and most of the intronic sequence. Each intron is flanked by the canonical GT-AG splice site dinucleotides. The length of the exons varies from 43 bp of exon 2 to 566 bp of exon 1 (Table 1) . Intron sizes range from 101 bp (intron 6) to 3.5 kb (intron 4). The exon-intron structure of ATB 0 is detailed. Splice acceptor and donor sequences are shown in boldface type. Size of each exon is also included.
a GeneBank accession no. Table 4 . The GT repeat lengths in each group were compared with those in the others showing similar results: the mean of the (GT) n allele was 167.1 in general population, 167.5 in CF-nonMI and 166.7 in CF-MI. The frequency of each allele was also compared vs the frequency of the rest of the alleles among the different groups. No statistical difference was detected, except for allele 167, which was significantly more frequent (w 2 = 0.2; P=0.02) when comparing general population and CF patients, but not between CF subgroups (w 2 =0.01;
P40.99).
Although the frequency of allele 169 was increased in the CF-MI subgroup (Table 4) , there was no statistical significance when compared with the general population (w 2 =0.13, P=0.14) nor with CF-nonMI (w 2 = 0.3; P=0.35). Analysis of the distribution of the (GT) n alleles in each group of individuals showed that they were not normally distributed (P=0.010). The results of applying the Kruskal-Wallis test showed no significant difference among the three groups (P=0.604). When a binary logistic regression model was fitted to the data, with the phenotype as the response and the GT repeat length as the predictor, no significant effect of the GT repeat length was observed (CF-MI/CF-nonMI P=0.25, estimated odds ratio=93 and 95% CI=0.82 ± 1.05; general population/CF P=0.93, estimated odds ratio=0.99 and 95% CI=0.89 ± 1.11; general population/CF-MI P=0.5, estimated odds ratio=0.95 and 95% CI=0.83 ± 1.09).
We have also analysed 606 bp of the 5'-UTR, the complete sequence of human ATB 0 coding exons and their respective intronic flanking regions for the presence of mutations in CF-MI and CF-nonMI individuals. The sequence differs from the published sequence of the human neutral amino acid transporter hATB 0 (GeneBank accession no. U53347). We confirmed the existence of four errors in the original sequence, as published previously 6 (accession no. AF105230), and detected two additional differences: the insertion of G in the position 129 (5'-UTR) and the presence of a point mutation (T4A), leucine changes to glutamine, in position 750. To further investigate these differences, we sequenced 25 additional cDNAs from lymphocytes from individuals of the general population (data not shown) confirming that they were errors in the original sequence of hATB 0 . A new nucleotide sequence (NM005628) is now available and is in agreement with our results. An additional comparison between U53347 and NM005628 sequences (using Blast N program) showed the presence of a C in position 410 of sequence U53347, that was absent in NM005628. We determined the presence of this nucleotide indicating that there is an error in NM005628 in the corresponding position (380insC).
On the other hand, several different SSCP migrating patterns were identified among 25 CF patients with MI. Sequencing of abnormal bands showed the presence of 14 nucleotide changes along the ATB 0 gene (Table 5) Table 5 . Nucleotide substitutions 272C4T, 337del6 and 349C4T in the 5'-UTR were found to be associated with the P17A mutation, while 1229-4A4G is associated to 1229-106A>G in unrelated patients both in CF-MI and CF-nonMI. In order to evaluate a potential involvement of these nucleotide changes in the intestinal phenotypic variation of the CF disease, we analysed the presence of these SNPs in 23 CF-nonMI subjects. We found similar frequencies as in CF-MI patients and no statistically significant differences for these changes (Table 5) .
Frequencies for P17A and V512L in the general population were also determined. Statistical analysis showed that the higher incidence for P17A and the lower incidence for V512L observed in the general population 
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were not significantly different when compared with the frequency in CF-MI subgroup ( Table 5 ).
The distribution of individuals with two mutations (P17A/ P17A, P17A/V512L) in the CF-MI and CF-nonMI groups indicated no association between these double heterozygous genotype and the presence or absence of MI phenotype (Table 5) . 14 hCFM1 statistically significant interval was defined as a region of 3.75 Mb (D19S408 ± D19S412) that presented statistically significant association to the modulation of the intestinal phenotype of CF. 17 This fact has allowed us to map ATB 0 more accurately, between 50107 and 50926 kb of chromosome 19 draft sequence (Figure 1 ). This location is within the hCFM1 syntenic region that comprises the locus that modulates the intestinal phenotype of CF patients localised in chromosome 19q13.2 ± 13.4. 14 Our RH panel results led us to place ATB 0 immediately telomeric to the 3.75 Mb region (D19S408 ± D19S412) inside the hCFM1 syntenic region (Figure 1 ), a region demonstrated to present the strongest linkage with MI.
14 ATB 0 was evaluated as a potential modulator of CFTR activity on the basis of the position in relation to the hCFM1 syntenic region, functional characteristics of the encoded protein and their apparent relevance to MI phenotype. In order to perform an exhaustive mutational analysis of the gene, we determined the genomic structure of ATB 0 that consists of eight exons whose sizes vary from 43 bp (exon 2) to 566 bp (exon 1). Due to the potential relationship of ATB 0 gene to the intestinal phenotypical variation of CF, we analysed a simple sequence repeat DNA polymorphism in ATB 0 3'-UTR (GT) n and examined the ATB 0 gene for sequence variations that could be related with the presence or absence of meconium ileus in CF patients. The estimation of the association of a specific allele of the 3'-UTR polymorphism with intestinal phenotype of CF showed no statistical differences in the CF-MI group as compared to CF-nonMI, nor in the general population (Table 4) . Only allele 167 was found in a statistically different frequency in the general population when compared with CF, suggesting that this gene may be modifying CF in general and not only the intestinal phenotype of CF. As regards sequence variations, 14 nucleotide changes were identified (Table 5) , 10 of them were found in the non-coding regions and four in the coding regions of the gene. Two of these nucleotide changes were translated into amino acid substitutions, P17A in exon 1, and V512L in exon 8. The first change implies the presence of a smaller and hydrophobic amino acid in position 17 and the second, in position 512, varies exclusively the size of the amino acid and not the charge. Moreover, these changes affect neither the conserved regions in the family of amino acid transporters (ex. ASCT1 present K instead of P in position 17 and E instead of V in position 512), nor the transmembrane domains of the protein, 7, 18 so that they are not predicted to greatly affect the properties of the protein. Although the groups of patients are fairly small (only 15 ± 20% of patients present MI), statistical analysis suggested that none of the changes identified is associated to the intestinal phenotype of CF, as their frequencies were found to be similar in both CF-MI and CF-nonMI subjects. The studies in CFTR knockout mice 13 showed that there was an increased number of mice homozygous for the syntenic region associated to the modulation of the intestinal problem. In our study, no association was determined between the presence of two mutations and a specific intestinal phenotype either. Our results suggest that there is no evidence to support that these ATB 0 variants alone contribute to the intestinal phenotypical variation of CF. Zielenski et al 14 found no particular allele or haplotype associated with the MI phenotype from the preliminary analysis of a potential transmission disequilibrium of hCFMI, suggesting the potential involvement of multiple variants or mutations on multiple loci at the modifier locus site. Our results may help to define precise haplotypes that could have a synergetic effect on other modifier loci in the same region. SNPs are stable inherited, biallelic, single base pair differences which are present in the human genome at a density of 1 to 10 per 1000 nucleotides. It is thought that these SNPs contribute to the functional heterogeneity in gene expression and protein activity among individuals. Although no particular allele or haplotype in the ATB 0 gene appears to be associated to CF-MI disease, new SNPs identified should be useful in segregation and linkage analysis in families affected by the impairment of neutral amino acid transport such as Hartnup disease, believed to be caused by a genetic defect in a specific system responsible for neutral amino acid transport across the brush-border membrane of renal and intestinal epithelium. Knowledge of DNA sequence variation may help us understand how genetic variability leads to functional variability, and will contribute to the development of new therapies in order to re-establish the normal phenotype.
